| Dr Henry C Skinner, MD | |
|
1155 Lisbon St, Lewiston, ME 04240-5025 | |
| (207) 783-9141 | |
| (207) 376-3808 |
| Full Name | Dr Henry C Skinner |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 1155 Lisbon St, Lewiston, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619949526 | NPI | - | NPPES |
| Entity Name | Bridgton Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154370153 PECOS PAC ID: 8123919099 Enrollment ID: O20040322000534 |
News Archive
Caudate hepatocellular carcinoma (HCC) has a poorer prognosis than HCC originating from other lobes, due to its proximity to the portal trunk and inferior vena cava, which facilitate intrahepatic and systemic spread early in the disease. Hepatic resection is considered, in principle, to be the first choice treatment. In order to improve surgical outcome, it is necessary to evaluate the potential risk factors affecting long-term survival and to establish guidelines for the appropriate use of hepatectomy for caudate lobectomy.
Research led by Jeff Gidday, PhD, Professor of Ophthalmology, Biochemistry, Neuroscience, and Physiology at LSU Health New Orleans School of Medicine, reports what is believed to be the first study in a mammalian model documenting the reprogramming of heritability to promote disease resilience in the next generation.
Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.
Venomtech® – a leading UK-based biotechnology company founded in 2010 – is harnessing the power of natural venoms produced by animals to generate compound libraries that are used in drug discovery studies.
Arizona State University researchers have developed a prosthetic device that literally puts the spring back into an amputee's step. The ASU scientists have developed and refined SPARKy (for spring ankle with regenerative kinetics) into a smart, active and energy storing below-the-knee (transbitial) prosthesis.
› Verified 9 days ago
| Entity Name | Central Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689653487 PECOS PAC ID: 2567379563 Enrollment ID: O20040324000441 |
News Archive
Caudate hepatocellular carcinoma (HCC) has a poorer prognosis than HCC originating from other lobes, due to its proximity to the portal trunk and inferior vena cava, which facilitate intrahepatic and systemic spread early in the disease. Hepatic resection is considered, in principle, to be the first choice treatment. In order to improve surgical outcome, it is necessary to evaluate the potential risk factors affecting long-term survival and to establish guidelines for the appropriate use of hepatectomy for caudate lobectomy.
Research led by Jeff Gidday, PhD, Professor of Ophthalmology, Biochemistry, Neuroscience, and Physiology at LSU Health New Orleans School of Medicine, reports what is believed to be the first study in a mammalian model documenting the reprogramming of heritability to promote disease resilience in the next generation.
Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.
Venomtech® – a leading UK-based biotechnology company founded in 2010 – is harnessing the power of natural venoms produced by animals to generate compound libraries that are used in drug discovery studies.
Arizona State University researchers have developed a prosthetic device that literally puts the spring back into an amputee's step. The ASU scientists have developed and refined SPARKy (for spring ankle with regenerative kinetics) into a smart, active and energy storing below-the-knee (transbitial) prosthesis.
› Verified 9 days ago
| Entity Name | Rumford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205991122 PECOS PAC ID: 3870583511 Enrollment ID: O20040514000890 |
News Archive
Caudate hepatocellular carcinoma (HCC) has a poorer prognosis than HCC originating from other lobes, due to its proximity to the portal trunk and inferior vena cava, which facilitate intrahepatic and systemic spread early in the disease. Hepatic resection is considered, in principle, to be the first choice treatment. In order to improve surgical outcome, it is necessary to evaluate the potential risk factors affecting long-term survival and to establish guidelines for the appropriate use of hepatectomy for caudate lobectomy.
Research led by Jeff Gidday, PhD, Professor of Ophthalmology, Biochemistry, Neuroscience, and Physiology at LSU Health New Orleans School of Medicine, reports what is believed to be the first study in a mammalian model documenting the reprogramming of heritability to promote disease resilience in the next generation.
Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.
Venomtech® – a leading UK-based biotechnology company founded in 2010 – is harnessing the power of natural venoms produced by animals to generate compound libraries that are used in drug discovery studies.
Arizona State University researchers have developed a prosthetic device that literally puts the spring back into an amputee's step. The ASU scientists have developed and refined SPARKy (for spring ankle with regenerative kinetics) into a smart, active and energy storing below-the-knee (transbitial) prosthesis.
› Verified 9 days ago
| Entity Name | Tri-county Mental Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215979158 PECOS PAC ID: 6103800131 Enrollment ID: O20040707000723 |
News Archive
Caudate hepatocellular carcinoma (HCC) has a poorer prognosis than HCC originating from other lobes, due to its proximity to the portal trunk and inferior vena cava, which facilitate intrahepatic and systemic spread early in the disease. Hepatic resection is considered, in principle, to be the first choice treatment. In order to improve surgical outcome, it is necessary to evaluate the potential risk factors affecting long-term survival and to establish guidelines for the appropriate use of hepatectomy for caudate lobectomy.
Research led by Jeff Gidday, PhD, Professor of Ophthalmology, Biochemistry, Neuroscience, and Physiology at LSU Health New Orleans School of Medicine, reports what is believed to be the first study in a mammalian model documenting the reprogramming of heritability to promote disease resilience in the next generation.
Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.
Venomtech® – a leading UK-based biotechnology company founded in 2010 – is harnessing the power of natural venoms produced by animals to generate compound libraries that are used in drug discovery studies.
Arizona State University researchers have developed a prosthetic device that literally puts the spring back into an amputee's step. The ASU scientists have developed and refined SPARKy (for spring ankle with regenerative kinetics) into a smart, active and energy storing below-the-knee (transbitial) prosthesis.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Henry C Skinner, MD 253 Main St, Yarmouth, ME 04096-6800 Ph: (207) 650-1393 | Dr Henry C Skinner, MD 1155 Lisbon St, Lewiston, ME 04240-5025 Ph: (207) 783-9141 |
News Archive
Caudate hepatocellular carcinoma (HCC) has a poorer prognosis than HCC originating from other lobes, due to its proximity to the portal trunk and inferior vena cava, which facilitate intrahepatic and systemic spread early in the disease. Hepatic resection is considered, in principle, to be the first choice treatment. In order to improve surgical outcome, it is necessary to evaluate the potential risk factors affecting long-term survival and to establish guidelines for the appropriate use of hepatectomy for caudate lobectomy.
Research led by Jeff Gidday, PhD, Professor of Ophthalmology, Biochemistry, Neuroscience, and Physiology at LSU Health New Orleans School of Medicine, reports what is believed to be the first study in a mammalian model documenting the reprogramming of heritability to promote disease resilience in the next generation.
Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.
Venomtech® – a leading UK-based biotechnology company founded in 2010 – is harnessing the power of natural venoms produced by animals to generate compound libraries that are used in drug discovery studies.
Arizona State University researchers have developed a prosthetic device that literally puts the spring back into an amputee's step. The ASU scientists have developed and refined SPARKy (for spring ankle with regenerative kinetics) into a smart, active and energy storing below-the-knee (transbitial) prosthesis.
› Verified 9 days ago
Alfonso Corona, M.D Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1155 Lisbon St, Lewiston, ME 04240 Phone: 207-783-9141 | |
Dr. Paula Claire Kirby-long, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 76 High St Ste 300, Lewiston, ME 04240 Phone: 207-795-5544 Fax: 207-795-5645 | |
Kimberly P Wells, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 93 Campus Ave, Lewiston, ME 04240 Phone: 207-777-8700 Fax: 207-777-8826 | |
Dr. David A Dettmann, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Ave, Suite 208, Lewiston, ME 04240 Phone: 207-777-8974 Fax: 207-777-8946 | |
Dr. Luke W Ballenger Iii, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 100 Campus Ave, Suite 208, Lewiston, ME 04240 Phone: 207-777-8974 Fax: 207-777-8946 | |
Annabel L Bradford, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 93 Campus Ave, Lewiston, ME 04240 Phone: 207-777-8700 | |
Ira M. Shapiro, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 100 Campus Ave, Suite 208, Lewiston, ME 04240 Phone: 207-777-8974 Fax: 207-777-8946 |